Know more... - Pancreatic Cancer India

More documents

Recommendations

Info

Dr Bhawna Sirohi’s CV 3. Low incidence of cardio toxicity following daunomycin and doxorubicin at a 10 year follow-up in March 1997 at Annual Conference of Bombay Haematology group at Bombay 4. Single centre evaluation of long term follow up of autologous stem cell transplantation for first remission adult ALL: potential for cure without excessive toxicity; Annual meeting of European Bone Marrow Transplantation (EBMT) Group, Innsbruck 6 th March 2000. 5. Central nervous system relapse after stem cell transplantation (SCT) for acute leukaemia beyond first remission; Annual meeting of EBMT Group, Innsbruck 6 th March, 2000. 6. CNS relapse after auto- and allo- stem cell transplant (SCT) for acute leukaemia beyond first CR. 5 th Annual Meeting of the European Haematology Association, June 2000. 7. High-dose mephalan with auto-transplantation in Myeloma patients with severe renal dysfunction (GFR
Dr Bhawna Sirohi’s CV 18. Results of randomised, cross over study comparing pegylated interferon with interferon-alpha2b in patients with myeloma,8 th Congress of EHA, Lyons, France 15 th June 2003 19. Serum free light chain assessment in myeloma patients in complete remission, 29 th EBMT Annual Meeting, Istanbul, Turkey, 21 st July 2003 20. Randomised, two-period cross over study comparing quality of life and toxicity of pegylated interferon with interferon-alpha2b in patients with myeloma, 29th EBMT Annual Meeting, Istanbul, Turkey, 22nd July 2003. 21. Effect of human growth hormone in haemato-oncology patients receiving intensive chemotherapy- a double-blind randomised placebo controlled trial , 23 rd joint meeting of British Endocrine societies , Brighton, 23 rd March 2004. 22. Long term use of Capecitabine in patients with locally recurrent or metastatic breast cancer: concept for metronomic chemotherapy, ESMO Lugano 2008 POSTER PRESENTATIONS: 1. A Phase I-II study evaluating the feasibility of acute lymphoblastic leukaemiatype intensive consolidation chemotherapy (UKALL XA) after initial C-VAMP and high-dose melphalan auto transplantation at VIIth International Multiple Myeloma Workshop, Stockholm, 2nd September 1999 2. The implications of compromised renal function at the time of presentation: A single centre study of 251 patients. Annual Meeting of American society of Haematology, New Orleans, December 7 1999. 3. Light chain disease (LCD): A different form of myeloma compared with IgG disease. Annual Meeting of American society of Haematology, New Orleans, December 7 1999. 4. High dose chemotherapy and autologous transplantation in myeloma patients aged 65 years and over: A case control comparison with younger patients. Annual Meeting of American society of Haematology, New Orleans, December 7, 1999. 5. A comparison of kinetics of paraprotein clearance: Rapid decline of paraprotein after high dose melphalan (HDM) versus infusional chemotherapy (IC) in previously untreated patients with IgG multiple myeloma. Annual meeting of EBMT Group, Innsbruck 6 h March, 2000. 6. High dose chemotherapy (HDT) and autologous transplantation in myeloma patients aged 65 years and over: A case control comparison with younger patients. Annual meeting of EBMT Group, Innsbruck 6 th March, 2000. 7. Glomerular filtration rate (GFR) as a surrogate marker for transplant related toxicity and overall outcome in patients of multiple myeloma (MM) homogenously treated with high dose melphalan (HDM) 200mg/m 2 . Annual meeting of EBMT Group, Innsbruck 6 th March, 2000. 8. Bence-Jones (BJ) Myeloma: A different form of myeloma compared to IgG and IgA myeloma. Annual meeting of EBMT Group, Innsbruck 6 th March, 2000. 9. The implication of compromised and normal renal function at presentation in myeloma. Annual meeting of EBMT Group, Innsbruck 6 th March, 2000. 10. Kinetics of paraprotein clearance: rapid decline of paraprotein after high-dose melphalan (HDM) compared to infusional chemotherapy in previously untreated patients with IgG myeloma. 5 th Annual Meeting of the European Haematology Association. 2000: 11. Glomerular filtration rate as a surrogate marker for transplant-related toxicity and overall outcome in patients with multiple myeloma homogenously treated with 13
Page 1 and 2: Dr Bhawna Sirohi’s CV CURRICULUM
Page 3 and 4: Dr Bhawna Sirohi’s CV I joined Gu
Page 5 and 6: Dr Bhawna Sirohi’s CV July 1992-A
Page 7 and 8: Dr Bhawna Sirohi’s CV Editor, Art
Page 9 and 10: Dr Bhawna Sirohi’s CV 1999- 2007:
Page 11: Dr Bhawna Sirohi’s CV trusts in U
Page 15 and 16: Dr Bhawna Sirohi’s CV High Incide
Page 17 and 18: Dr Bhawna Sirohi’s CV 48. Implica
Page 19 and 20: Dr Bhawna Sirohi’s CV 2048 A rand
Page 21 and 22: Dr Bhawna Sirohi’s CV 5. Principl
Page 23 and 24: Dr Bhawna Sirohi’s CV 56. Role of
Page 25 and 26: Dr Bhawna Sirohi’s CV 106. Panel
Page 27 and 28: Dr Bhawna Sirohi’s CV 16. Sirohi
Page 29 and 30: Dr Bhawna Sirohi’s CV A, Niederwi
Page 31 and 32: Dr Bhawna Sirohi’s CV 61. Sirohi

Know more... - Pancreatic Cancer India

Create successful ePaper yourself

Delete template?

Save as template?